ABBV - AbbVie Inc.
Close
192.87
0 0%
Share volume: 2,687,658
Last Updated: Tue 24 Dec 2024 06:00:15 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.45%
PREVIOUS CLOSE
CHG
CHG%
$192.87
-14.44
0.08%
Fundamental analysis
54%
Profitability
50%
Dept financing
50%
Liquidity
12%
Performance
71%
Performance
5 Days
4.01%
1 Month
0.75%
3 Months
-7.81%
6 Months
3.27%
1 Year
15.13%
2 Year
9.45%
Key data
Stock price
$192.87
DAY RANGE
$177.88 - $180.15
52 WEEK RANGE
$154.97 - $207.32
52 WEEK CHANGE
$15.37
DIVIDEND
$1.55
EX-DIVIDEND DATE
07/15/2024
NEXT EARNINGS DATE
10/25/2024
Company detail
CEO: Richard A. Gonzalez
Region: US
Website: abbvie.com
Employees: 50,000
IPO year: -
Issue type: Common Stock
Market: NYSE
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: abbvie.com
Employees: 50,000
IPO year: -
Issue type: Common Stock
Market: NYSE
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism.
Recent news